Ramucirumab Meets Primary Endpoints in Phase III Lung Cancer Trial
Combination treatment with docetaxel improves survival (February 19)
A global phase III study of ramucirumab (Eli Lilly) in combination with chemotherapy in patients with second-line non–small-cell lung cancer (NSCLC) has shown a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared with the control arm of placebo plus docetaxel.
The study also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared with the control arm.
The randomized, double-blind REVEL trial compared ramucirumab and docetaxel with placebo and docetaxel in NSCLC patients whose disease had progressed after the failure of prior platinum-based chemotherapy for locally advanced or metastatic disease. The study included patients with nonsquamous and squamous NSCLC. The trial’s primary endpoint was overall survival, and secondary endpoints included progression-free survival, the objective response rate, quality of life, and safety.
Ramucirumab is a human, receptor-targeted antibody that specifically blocks the vascular endothelial growth factor (VEGF) receptor 2, thereby inhibiting the downstream signaling involved in the formation and maintenance of aberrant blood vessels that supply blood to tumors. Ramucirumab is being investigated in clinical trials as a single agent and in combination with other anticancer therapies for the treatment of multiple tumor types.
Source: Eli Lilly; February 19, 2014.